Every 10-Q that ESCALON MEDICAL CORP (ESMC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ESMC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ESMC filings page.
Escalon Medical Corp. reported lower sales but a sharp profit boost for the quarter ended March 31, 2026, driven by a one-time asset sale. Quarterly net revenue fell to $2.6 million from $3.5 million as product sales declined across Sonomed and Trek lines, reflecting backorders from a key vendor and softer demand. Cost of revenue rose as a percentage of sales, pressuring underlying margins.
The company sold software-related assets of its AXIS platform for $3.0 million, generating a pretax gain of about $2.8 million and lifting net income to $2.4 million for the quarter and $2.2 million for the nine months. Cash increased to $3.3 million, and working capital improved to $4.0 million, but operations used cash and the core business posted a nine‑month operating loss. Management disclosed substantial doubt about Escalon’s ability to continue as a going concern and reported a material weakness in internal control over inventory valuation, highlighting ongoing financial and control risks despite stronger liquidity.
Escalon Medical Corp. reported modest growth but weaker profitability for the quarter and six months ended December 31, 2025. Quarterly revenue rose to $3.6M, up from $3.2M a year earlier, and six‑month revenue increased to $6.3M from $6.0M, driven mainly by higher Sonomed product sales.
Despite this, cost of revenue climbed, with gross margin slipping as cost of revenue reached 57.3% of six‑month sales versus 53.6% last year. The company earned quarterly net income of $97,677, but posted a six‑month net loss of $142,175 compared with prior‑year profit, as marketing, general and administrative expenses and research and development both increased.
Cash pressure remains significant. Escalon used $432,407 in operating cash over six months, ending with only $337,434 of cash and a working capital position of $1.7M. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern, citing recurring losses, negative operating cash flows and weak liquidity, partly offset by a new $100,000 related‑party loan.
Subsequent to quarter‑end, Escalon completed a $3,000,000 asset sale of AXIS software‑related assets to Optos, receiving an initial $1,000,000 milestone payment in January 2026, with a gain expected in the following quarter. The company also fully repaid its TD Bank term loan using restricted cash. However, a material weakness in internal controls over inventory valuation remains unresolved.
Escalon Medical Corp. (ESMC) filed its Q1 FY2026 10‑Q, reporting revenue of $2,675,321, down 3.8% year over year. Product sales were $2,536,881 and service plans added $138,440. Cost of revenue was $1,554,579 (58.1% of revenue), reflecting a less favorable mix. The quarter produced a net loss of $239,852, with a loss applicable to common stockholders of $252,858, or $0.03 per basic and diluted share, compared with $0.01 a year ago.
Cash was $615,791 plus restricted cash of $256,582; working capital was $1,694,000 and equity totaled $1,675,255. Operating cash flow was positive at $85,008, helped by lower inventories and receivables. Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing historic losses, liquidity ratios, and tariff-related uncertainty.
After quarter‑end, the company repaid $113,960 on its TD Bank loan using restricted cash, releasing $142,622. In November 2025, it entered a $100,000 related‑party loan at 14% for three months, then Prime+2% if extended. Management also reported a continuing material weakness in internal control over inventory valuation precision.